Almirall Launches a Call for Collaboration in Its Research into Skin Diseases

Almirall continues the fight against skin diseases. The Spanish pharmaceutical company continues to look for collaborators to study key pathological mechanisms in skin diseases, according to the company statement.

In this sense, Almirall has launched this Tuesday, October 24th, its eighth call for AlmirallShare, its open innovation platform, to identify projects focused on research into key pathological mechanisms that could yield innovative therapies for the treatment of various skin diseases.

With this call, Almirall aims to explore and identify, in collaboration with external partners, different mechanisms and signaling pathways common to different organs and tissues, which can be transferred to dermatological diseases of interest. Possible conditions include atopic dermatitis, hidradenitis suppurativa, and vitiligo, among others.

Scientists affiliated with universities, research centers, start-ups, and biotechnology and pharmaceutical companies from around the world can submit their proposals until January 31, 2024. A team of Almirall scientists will evaluate the proposals submitted to select those that best fit the requirements of the call and have the potential to establish a long-term collaboration with the company.

This initiative has attracted more than 1,100 scientists and has received around 600 proposals from more than sixty countries and has allowed Almirall to obtain increasing recognition from the scientific community, reinforcing the company’s profile as a trusted partner for future collaborations.

Read more about Almirall and find the latest financial news of the day with our companion app Born2Invest.

Almirall’s total income in 2022 was €878.5 million

“Through AlmirallShare, we have achieved valuable collaborations that reinforce our internal efforts to improve the lives of people with skin diseases; “This year we are going one step further by focusing on understanding the key pathological mechanisms that drive skin diseases,” says Maribel Crespo, Head of AlmirallShare.

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate dermatology research collaborations and find innovative solutions in medical dermatology. Through this unique platform, the company has established valuable collaborations with scientists, universities, public and private institutions, hospitals, and biotechnology companies.

To date, the company has established eight collaboration projects with different institutions, including collaborations for new therapies (Idibaps, University of Turin, University of South Australia, Hospital de la Santa Creu i Sant Pau), new targets (Dublin City University, University of Namur) and new preclinical models (University College Dublin, University of Sheffield).

Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patient needs through science to improve their lives.

The company, founded in 1944 and based in Barcelona, ​​is listed on the Spanish Stock Exchange. Throughout its 79 years of history. Almirall has a direct presence in 21 countries and strategic agreements in more than 70 and has approximately 1,800 employees. Total revenue in 2022 was €878.5 million.

__

(Featured image by Bermix Studio via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.